Ipamorelin

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the ghrelin receptor (GHSR-1a), stimulating the pituitary to release growth hormone. It was among the first GH secretagogues shown to produce meaningful GH pulses without significantly elevating cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from earlier GH-releasing peptides such as GHRP-2 and GHRP-6 [1].

Ipamorelin is not FDA-approved for any indication. It is available in the United States only as a compounded prescription medication. In clinical practice it is most commonly prescribed off-label for body composition support, recovery, and sleep quality, often in combination with a GHRH analog such as CJC-1295 or sermorelin.

The evidence base is predominantly preclinical (animal studies and in vitro experiments) with a single published human randomized controlled trial assessing a GI-motility endpoint — not body composition or anti-aging outcomes. Clinicians and patients should weigh this limited evidence carefully. Evidence grade: C.

Ipamorelin mimics the endogenous appetite-regulating hormone ghrelin by binding to GHSR-1a receptors on anterior pituitary somatotrophs. This activates a Gq/11-coupled signaling cascade, raising intracellular calcium and triggering GH secretion in a pulse-like manner [1]. The selectivity of ipamorelin is its defining characteristic: at pharmacologically relevant doses it does not meaningfully stimulate ACTH or cortisol release, in contrast to GHRP-2 and GHRP-6, which reliably elevate these hormones [1].

When ipamorelin is combined with a GHRH analog (which acts on the separate GHRHR receptor), the two pathways are synergistic — producing larger GH pulses than either agent alone. Plasma half-life in humans is approximately two hours [2], supporting once- to three-times-daily dosing regimens used in clinical practice.

The foundational human data are pharmacokinetic, not efficacy-based. Gobburu et al. characterized the PK-PD relationship of ipamorelin in healthy human volunteers, demonstrating dose-dependent GH release that was reproducible across dosing intervals [2]. This established that ipamorelin does stimulate GH in humans, but the study was not designed to assess clinical endpoints such as lean mass, fat loss, or quality of life.

The only published human RCT evaluating a clinical endpoint is Beck et al. (2014), a prospective, randomized, controlled proof-of-concept study of ipamorelin for the management of postoperative ileus in bowel-resection patients (n=35). Ipamorelin showed a statistically significant reduction in time to GI recovery compared to placebo [3]. This GI-motility indication is distinct from the body-composition or anti-aging applications promoted in wellness contexts.

Animal studies provide mechanistic support but are not directly applicable to human clinical outcomes. In adult rats, ipamorelin counteracted glucocorticoid-induced decreases in bone formation, consistent with GH-mediated anabolic effects [4]. A rodent model of postoperative ileus confirmed dose-dependent prokinetic effects [5]. In steroid-treated rats, ipamorelin improved nitrogen balance and reduced urea synthesis, suggesting protein-anabolic activity [6]. A 2024 ferret model found ipamorelin reduced cisplatin-induced weight loss, pointing to potential utility in cachexia models [7].

No controlled human trial has measured lean body mass accrual, fat-mass reduction, sleep architecture, or bone density as a primary endpoint for ipamorelin. Claims about these outcomes in healthy adults are extrapolated from GH physiology and anecdotal clinical reports.

Compounding prescribers commonly administer ipamorelin at 100–300 mcg per subcutaneous injection, one to three times daily. Common timing includes peri-workout administration and a dose before sleep to coincide with the natural nocturnal GH pulse. When combined with CJC-1295 or sermorelin, doses at the lower end of this range are typical [2].

Because no FDA-approved dosing protocol exists, clinical protocols vary substantially among prescribers. IGF-1 monitoring at baseline and periodically during therapy is used by some practitioners to confirm a biological response. Oral formulations have not been studied; all published human pharmacokinetic data involve intravenous or subcutaneous administration.

Ipamorelin is available only through compounding pharmacies in the U.S. and is not subject to the manufacturing standards applied to FDA-approved drugs. Variable potency, sterility, and purity across compounders are inherent risks. The clean hormonal-selectivity profile — minimal cortisol and prolactin stimulation — is one of the primary reasons clinicians prefer ipamorelin over older GH secretagogues [1].

Reported side effects from clinical use and anecdotal reports include injection-site reactions, transient water retention, mild headache, and flushing. Long-term safety data in humans are essentially absent; no study has followed subjects on ipamorelin for more than a few weeks. As with all agents that elevate GH and IGF-1, caution is warranted in individuals with active or prior malignancy. Ipamorelin should not be used during pregnancy. All use in healthy adults for body-composition or anti-aging purposes is off-label.